0001855763-24-000010.txt : 20240510
0001855763-24-000010.hdr.sgml : 20240510
20240510172401
ACCESSION NUMBER: 0001855763-24-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240426
FILED AS OF DATE: 20240510
DATE AS OF CHANGE: 20240510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carle Vanessa
CENTRAL INDEX KEY: 0001855763
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39874
FILM NUMBER: 24936109
MAIL ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lexaria Bioscience Corp.
CENTRAL INDEX KEY: 0001348362
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 202000871
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0831
BUSINESS ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
BUSINESS PHONE: 250-765-6424
MAIL ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
FORMER COMPANY:
FORMER CONFORMED NAME: LEXARIA CORP.
DATE OF NAME CHANGE: 20080229
FORMER COMPANY:
FORMER CONFORMED NAME: Lexaria Corp.
DATE OF NAME CHANGE: 20051229
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2024-04-26
0
0001348362
Lexaria Bioscience Corp.
LEXX
0001855763
Carle Vanessa
100 - 740 MCCURDY ROAD
KELOWNA
A1
V1X 2P7
BRITISH COLUMBIA, CANADA
0
1
0
0
Secretary
0
common shares
67
D
Warrants
36
2019-11-13
2024-11-13
Common Shares
67
67
D
Stock Options
3
2021-04-26
2026-04-26
Common Shares
12500
12567
D
Stock Options
3
2021-06-08
2026-06-08
Common Shares
5000
17567
D
Stock Options
3
2021-09-01
2026-09-01
Common Shares
10000
27567
D
Stock Options
2.91
2022-08-29
2027-08-29
Common Shares
12500
40067
D
Stock Options
1.15
2023-10-26
2028-10-26
Common Shares
12500
52567
D
Stock Options
2.36
2024-04-26
4
A
0
10000
0
A
2024-04-26
2029-04-26
Common Shares
10000
62567
D
Repriced from $5.31 pursuant to shareholder approval received May 9, 2023
Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
Repriced from $6.23 pursuant to shareholder approval received May 9, 2023
/Vanessa Carle/
2024-05-10